Comparing Pyxis Oncology (PYXS) & Its Peers

Pyxis Oncology (NASDAQ:PYXS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Pyxis Oncology to related businesses based on the strength of its risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pyxis Oncology and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1	1	8	0	2.70
Pyxis Oncology Competitors	9770	15029	45237	1570	2.54

Pyxis Oncology presently has a consensus target price of $8.75, suggesting a potential upside of 383.43%. As a group, “Biotechnology” companies have a potential upside of 95.44%. Given Pyxis Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than its competitors.

Volatility & Risk

Pyxis Oncology has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Pyxis Oncology’s competitors have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Pyxis Oncology and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Pyxis Oncology Competitors	-9,054.31%	-198.21%	-30.53%

Earnings & Valuation

This table compares Pyxis Oncology and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pyxis Oncology	$13.86 million	-$79.62 million	-1.28
Pyxis Oncology Competitors	$689.46 million	$10.37 million	-10.05

Pyxis Oncology’s competitors have higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Pyxis Oncology competitors beat Pyxis Oncology on 7 of the 12 factors compared.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.